Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.76 |
| ▸ | SCN1A | P35498 | 2/20 | 0.76 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.76 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15535631 | 0.88 | SCN9A (1.00) | SCN9ASCN5ASCN1ASCN2ASCN8A | |
| SCHEMBL16448506 | 0.87 | SCN9A (1.00) | SCN9ASCN5A | |
| SCHEMBL15536031 | 0.86 | SCN9A (1.00) | SCN9ASCN5ASCN1ASCN2ASCN8A | |
| SCHEMBL15535698 | 0.86 | SCN9A (1.00) | SCN9ASCN5ASCN1ASCN2ASCN8A | |
| SCHEMBL16448518 | 0.83 | SCN9A (1.00) | SCN9ASCN5ASCN1ASCN2ASCN8A | |
| SCHEMBL15536421 | 0.83 | SCN9A (1.00) | SCN9ASCN5ASCN1ASCN2ASCN8A | |
| SCHEMBL15537549 | 0.83 | SCN9A (1.00) | SCN9ASCN5A | |
| SCHEMBL15558495 | 0.82 | SCN9A (1.00) | SCN9ASCN5ASCN1ASCN2ASCN8A | |
| SCHEMBL16448508 | 0.82 | SCN9A (1.00) | SCN9ASCN5A | |
| SCHEMBL16449071 | 0.82 | SCN9A (1.00) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002017-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| EP-2855428-A1 | N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN | Genentech, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8952169-B2 | N-substituted benzamides and methods of use thereof | XENON PHARMACEUTICALS INC. (CA) | 2015-02-10 | — | — | US | disclosed |
| US-8952169-B2 | N-substituted benzamides and methods of use thereof | XENON PHARMACEUTICALS INC. (CA) | 2015-02-10 | — | — | US | disclosed |
| WO-2013177224-A1 | N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN | GENENTECH, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002017-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SNRPD2 | SCN9A 1210/4885SCN5A 467/4885SCN1A 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.